| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 141, 531-538, Copyright © 1992 by American Society for Investigative Pathology
REGULAR ARTICLES |
K Beiske, AT Myklebust, S Aamdal, R Langholm, E Jakobsen and O Fodstad
Norwegian Radium Hospital, Oslo.
An immunocytochemical method, involving four monoclonal antibodies (MAbs) previously selected for their specific binding to small cell lung cancer (SCLC) cells in human bone marrow, was used for detection of bone marrow metastases in 81 patients with diagnosed SCLC. This procedure was compared with two routine morphologic methods with regard to diagnostic efficiency and sensitivity. Bone marrow involvement was found in 26 patients (32%), one of which had limited disease according to conventional clinical criteria. Eight of the positive cases were exclusively diagnosed by immunocytochemistry, whereas the histologic and cytologic methods separately identified two patients each. Immunocytochemistry had a detection level of tumor cells in the mononuclear cell fraction of approximately 1-2%, whereas no patients with less than 10% immunocytologically detectable tumor cells were diagnosed by cytomorphologic examination of bone marrow aspirates. Evidence was obtained that the diagnostic efficiency of any method increased with the number of samples examined. Of the four MAbs used, the anti-NCAM antibody, MOC-1, labeled tumor cells in all immunologically positive patients, and in all but one of these patients all cytologically confirmed tumor cells were stained. The antibodies MOC-31, which recognize a cluster-2 antigen, and NrLu10 bound nearly all tumor cells in most cases, whereas MLuC1 only diagnosed tumor cells in a fraction of the patients. The results show that the immunocytochemical application of these antibodies is superior to morphologic techniques in detecting SCLC bone marrow metastases. Further use of the method might provide prognostically and therapeutically useful information.
This article has been cited by other articles:
 |
|
 |
|
  W. Janni, B. Rack, K. Lindemann, and N. Harbeck Detection of Micrometastatic Disease in Bone Marrow: Is It Ready for Prime Time? Oncologist, August 1, 2005; 10(7): 480 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. S. Bruland, H. Hoifodt, G. Saeter, S. Smeland, and O. Fodstad Hematogenous Micrometastases in Osteosarcoma Patients Clin. Cancer Res., July 1, 2005; 11(13): 4666 - 4673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Taback, A. E. Giuliano, N. M. Hansen, F. R. Singer, S. Shu, and D. S. B. Hoon Detection of Tumor-Specific Genetic Alterations in Bone Marrow from Early-Stage Breast Cancer Patients Cancer Res., April 15, 2003; 63(8): 1884 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Elias Hematopoietic Stem Cell Transplantation for Small Cell Lung Cancer* Chest, December 1, 1999; 116(suppl_3): 531S - 538S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pelosi, F. Pasini, F. Pavanel, E. Bresaola, I. Schiavon, and A. Iannucci Effects of Different Immunolabeling Techniques on the Detection of Small-cell Lung Cancer Cells in Bone Marrow J. Histochem. Cytochem., August 1, 1999; 47(8): 1075 - 1088. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Pantel, R. J. Cote, and O. Fodstad Detection and Clinical Importance of Micrometastatic Disease J Natl Cancer Inst, July 7, 1999; 91(13): 1113 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Elias, J. Ibrahim, A. T. Skarin, C. Wheeler, M. McCauley, L. Ayash, P. Richardson, L. Schnipper, K. H. Antman, and E. Frei III Dose-Intensive Therapy for Limited-Stage Small-Cell Lung Cancer: Long-Term Outcome J. Clin. Oncol., April 1, 1999; 17(4): 1175 - 1175. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
